Response to: Ranibizumab vs. pegaptanib: a cost-effectiveness study?
Luis Javier Hernández-PastorVolume:
248
Langue:
english
Pages:
1
DOI:
10.1007/s00417-010-1393-y
Date:
November, 2010
Fichier:
PDF, 47 KB
english, 2010